BTIG analyst Thomas Shrader maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) yesterday and set a price target of $48.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thomas Shrader has given his Buy rating due to a combination of factors including promising upcoming readouts and advancements in Arcturus Therapeutics’ mRNA technology. The company’s mRNA-mediated protein replacement therapies are expected to show significant progress in the coming weeks, with preclinical data suggesting effective delivery to target organs, which reduces risk. Additionally, Arcturus has developed novel assays that could improve the clarity of results for OTC deficiency, potentially allowing for better differentiation between patient conditions.
Moreover, the company’s approach to COVID vaccine development, which focuses on safety through lower levels of RNA and lipid adjuvants, positions it as a strong candidate in the field. The anticipated readouts for cystic fibrosis treatments also show promise, with safety data supporting potential advancements. These factors, combined with a valuation based on a discounted cash flow model, support Shrader’s positive outlook on Arcturus Therapeutics.
In another report released on June 9, Citi also maintained a Buy rating on the stock with a $47.00 price target.
ARCT’s price has also changed moderately for the past six months – from $16.240 to $12.870, which is a -20.75% drop .